Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):220. doi.org/10.1186/s13059-017-1349-1
Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH (2018) Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology 7(10):e1468956. doi.org/10.1080/2162402x.2018.1468956
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A (2016) Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):249. doi.org/10.1186/s13059-016-1113-y
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. doi.org/10.1016/j.immuni.2013.10.003
Binnewies M, Roberts EW, Kersten K, Chan V (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550. doi.org/10.1038/s41591-018-0014-x
Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA (2014) AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med 12:216. doi.org/10.1186/s12967-014-0216-z
Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 102(2):419–424. doi.org/10.1073/pnas.0408197102
D’Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E (2014) The mitotic kinase Aurora–a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells. Oncogene 33(5):599–610. doi.org/10.1038/onc.2012.628
de Souza VB, Kawano DF (2020) Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy. Biochim Biophys Acta 1:129448. doi.org/10.1016/j.bbagen.2019.129448
Doncheva NT, Morris JH (2019) Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 18(2):623–632. doi.org/10.1021/acs.jproteome.8b00702
Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12(5):349–361. doi.org/10.1038/nrc3218
Garnis C, Buys TP, Lam WL (2004) Genetic alteration and gene expression modulation during cancer progression. Mol Cancer 3:9. doi.org/10.1186/1476-4598-3-9
Gide TN, Wilmott JS, Scolyer RA, Long GV (2018) Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res 24(6):1260–1270. doi.org/10.1158/1078-0432.ccr-17-2267
Goos JA, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Carvalho B, van den Tol MP, Verheul HM, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ (2013) Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer 109(9):2445–2452. doi.org/10.1038/bjc.2013.608
Guo M, Lu S, Huang H, Wang Y, Yang MQ, Yang Y, Fan Z, Jiang B, Deng Y (2018) Increased AURKA promotes cell proliferation and predicts poor prognosis in bladder cancer. BMC Syst Biol 12(Suppl 7):118. doi.org/10.1186/s12918-018-0634-2
Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347(20):1593–1603. doi.org/10.1056/NEJMra021902
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi.org/10.1016/j.cell.2011.02.013
Jhunjhunwala S, Hammer C (2021) Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer 21(5):298–312. doi.org/10.1038/s41568-021-00339-z
Kalaora S, Nagler A, Wargo JA (2022) Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. doi.org/10.1038/s41568-022-00442-9
Keirsse J, Van Damme H, Van Ginderachter JA, Laoui D (2017) Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. J Leukoc Biol 102(2):317–324. doi.org/10.1189/jlb.4MR1116-466R
Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517. doi.org/10.1146/annurev.immunol.021908.132710
Li MO, Flavell RA (2008) TGF-beta: a master of all T cell trades. Cell 134(3):392–404. doi.org/10.1016/j.cell.2008.07.025
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS (2020) TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48(W1):W509-w514. doi.org/10.1093/nar/gkaa407
Linares MA, Zakaria A, Nizran P (2015) Skin cancer. Prim Care 42(4):645–659. doi.org/10.1016/j.pop.2015.07.006
Liu ZG, Yi W, Tao YL, Chan HC, Zeng MS, Xia YF (2012) Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution. Oncol Lett 3(6):1237–1244. doi.org/10.3892/ol.2012.660
Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY (2018) GSCALite: a web server for gene set cancer analysis. Bioinformatics (oxford, England) 34(21):3771–3772. doi.org/10.1093/bioinformatics/bty411
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M (2018) Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173(2):338-354.e315. doi.org/10.1016/j.cell.2018.03.034
Mehdi A, Rabbani SA (2021) Role of methylation in pro- and anti-cancer immunity. Cancers. doi.org/10.3390/cancers13030545
Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J (2018) MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics 10(3):277–288. doi.org/10.2217/epi-2017-0118
Nagy Á, Győrffy B (2021) muTarget: a platform linking gene expression changes and mutation status in solid tumors. Int J Cancer 148(2):502–511. doi.org/10.1002/ijc.33283
Pandey PR, Young KH, Kumar D (2022) RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Mol Cancer 21(1):58. doi.org/10.1186/s12943-022-01528-6
Panicker RC, Coyne AG, Srinivasan R (2019) Allosteric targeting of Aurora A kinase using small molecules: a step forward towards next generation medicines? Curr Med Chem 26(13):2234–2242. doi.org/10.2174/0929867324666170727120315
Puig-Butille JA, Vinyals A, Ferreres JR, Aguilera P, Cabré E, Tell-Martí G, Marcoval J, Mateo F, Palomero L, Badenas C, Piulats JM, Malvehy J, Pujana MA, Puig S, Fabra À (2017) AURKA overexpression is driven by FOXM1 and MAPK/ERK activation in melanoma cells harboring BRAF or NRAS mutations: impact on melanoma prognosis and therapy. J Invest Dermatol 137(6):1297–1310. doi.org/10.1016/j.jid.2017.01.021
Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, Xu C, Forget MA, Haymaker C, Khalili JS, Satani N, Muller F, Cooper LJN, Overwijk WW, Amaria RN, Bernatchez C, Heffernan TP, Peng W, Roszik J, Hwu P (2021) Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother 70(4):1101–1113. doi.org/10.1007/s00262-020-02748-9
Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW (2010) CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18(5):485–498. doi.org/10.1016/j.ccr.2010.10.002
Scarpini S, Rouprêt M, Renard-Penna R, Camparo P, Cussenot O, Compérat E (2012) Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 30(2):182–187. doi.org/10.1016/j.urolonc.2009.12.003
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S (2018) Melanoma. Lancet (london, England) 392(10151):971–984. doi.org/10.1016/s0140-6736(18)31559-9
Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K (2021) Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22(2):205–215. doi.org/10.1038/s41590-020-00834-9
Seoane J, Gomis RR (2017) TGF-β family signaling in tumor suppression and cancer progression. Cold Spring Harbor Perspect Biol. doi.org/10.1101/cshperspect.a022277
Siegel RL, Miller KD (2019) Cancer statistics. CA A Cancer J Clin 69(1):7–34. doi.org/10.3322/caac.21551
Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, List M, Aneichyk T (2019) Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics (oxford, England) 35(14):i436–i445. doi.org/10.1093/bioinformatics/btz363
Umene K, Yanokura M, Banno K, Irie H, Adachi M, Iida M, Nakamura K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D (2015) Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. Int J Oncol 46(4):1498–1506. doi.org/10.3892/ijo.2015.2842
Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A (2016) Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment. J Natl Cancer Inst. doi.org/10.1093/jnci/djv406
Wang M, Ngo V, Wang W (2021) Deciphering the genetic code of DNA methylation. Brief Bioinform. doi.org/10.1093/bib/bbaa424
Xu J, Wu X, Zhou WH, Liu AW, Wu JB, Deng JY, Yue CF, Yang SB, Wang J, Yuan ZY, Liu Q (2013) Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS ONE 8(2):e56919. doi.org/10.1371/journal.pone.0056919
Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, Liang D, Lei H, Subrata S, Kelley KW, Lam EW, Jin B, Liu Q (2016) Aurora-A kinase: a potent oncogene and target for cancer therapy. Med Res Rev 36(6):1036–1079. doi.org/10.1002/med.21399
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612. doi.org/10.1038/ncomms3612
Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, Xu L, Luo T, Yan H, Long Z, Shi A, Zhao T, Xiao Y, Li X (2019) CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res 47(D1):D900-d908. doi.org/10.1093/nar/gky939
Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807–821. doi.org/10.1038/s41423-020-0488-6
Read more here: Source link